PGI28 Cost-Effectiveness of Simeprevir Vs. Telaprevir for The Triple Therapy of Hepatitis C In Kazakhstan

Abstract

Hepatitis C Virus(HCV) is a growing health problem in the world. The aim of this study is to estimate a cost-effectiveness of a triple therapy(TT) with simeprevir compared to a TT with telaprevir for the previously treated with double therapy HCV patients in Kazakhstan.